Quarterly ResultAug 13, 2026, 04:14 PM
RenovoRx Q2 Revenue $909K, Up 115%; Raises 2026 Guidance
AI Summary
RenovoRx, Inc. reported record second-quarter 2026 financial results, with revenue reaching $909,000, a 115% increase year-over-year and 61% sequentially. The company raised its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million. Operational highlights include the expansion of RenovoCath use to sarcoma patients, full enrollment in the Phase III TIGeR-PaC trial, and an increase to 21 active commercial cancer center customers.
Key Highlights
- RenovoRx Q2 2026 revenue was $909,000, up 115% year-over-year.
- Full-year 2026 revenue guidance raised to $3.75 million-$4.25 million.
- Net loss per share improved to $0.06 in Q2 2026 from $0.08 in Q2 2025.
- Active commercial cancer centers increased to 21, up 30% from Q1 2026.
- First RenovoCath treatment delivered for sarcoma, expanding beyond pancreatic cancer.
- Phase III TIGeR-PaC trial achieved full enrollment; topline data expected H2 2027.
- Cash and cash equivalents were $9.5 million as of June 30, 2026.
Price Impact
More from RNXT